GLENERIC
DEAD

Serial Number

77783471

Owner

Glenmark Pharmaceuticals Limited

Attorney

Howard J. Shire

Filing Date

Jul 17, 2009

Add to watchlist:

No watchlists yet
View on USPTO

GLENERIC Trademark

Serial Number: 77783471

GLENERIC is a trademark filed by Glenmark Pharmaceuticals Limited on July 17, 2009. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Glenmark Pharmaceuticals Limited (11 trademarks)

2/B Mahalaxmi Chamber 22
Mumbai , IN

Entity Type: 03

Trademark Details

Filing Date

July 17, 2009

Registration Date

Not Registered

Published for Opposition

August 17, 2010

Goods & Services

Pharmaceuticals and Medicinal preparations, namely, opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 14, 2012 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 14, 2012 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 15, 2011 EXRA
SOU EXTENSION 2 GRANTED
Oct 14, 2011 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 13, 2011 AITU
SOU EXTENSION 2 FILED
Oct 12, 2011 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 12, 2011 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 9, 2011 EXRA
SOU EXTENSION 1 GRANTED
Mar 7, 2011 EX1G
SOU EXTENSION 1 FILED
Mar 7, 2011 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 7, 2011 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 12, 2010 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 17, 2010 NPUB
PUBLISHED FOR OPPOSITION
Aug 17, 2010 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 9, 2010 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2010 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 9, 2010 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 9, 2010 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 9, 2010 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 9, 2010 CNEA
DATA MODIFICATION COMPLETED
Jun 5, 2010 DMCC
ASSIGNED TO LIE
Jun 3, 2010 ALIE
TEAS/EMAIL CORRESPONDENCE ENTERED
May 27, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 27, 2010 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 27, 2010 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 27, 2010 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 27, 2010 GNSL
SUSPENSION LETTER WRITTEN
Apr 27, 2010 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 14, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2009 GNRN
NON-FINAL ACTION E-MAILED
Oct 20, 2009 GNRT
NON-FINAL ACTION WRITTEN
Oct 20, 2009 CNRT
ASSIGNED TO EXAMINER
Oct 20, 2009 DOCK
NOTICE OF PSEUDO MARK MAILED
Jul 22, 2009 MPMK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 21, 2009 NWOS
NEW APPLICATION ENTERED
Jul 21, 2009 NWAP